🚀 VC round data is live in beta, check it out!
Largest Health & Beauty Public Companies
Benchmark revenue and EBITDA valuation multiples for public comps like
AbbVie, Procter & Gamble, L'Oreal, Novo Nordisk and Unilever.
 | $206 | +6% | $365B | $427B | 6.8x | 16.1x | ||
| $144 | -12% | $334B | $360B | 4.2x | 15.1x | ||
 | $419 | -6% | $224B | $226B | 4.3x | 17.9x | ||
 | $38 | -43% | $167B | $183B | 3.8x | 8.0x | ||
 | $58 | -19% | $126B | $152B | 2.5x | 11.2x | ||
| $233 | -20% | $107B | $120B | 3.5x | 14.4x | ||
| $84 | -9% | $67B | $75B | 3.6x | 14.9x | ||
 | $23 | -11% | $53B | $52B | 7.5x | 32.4x | ||
 | $200 | +64% | $47B | $49B | 8.9x | 37.0x | ||
 | $47 | +76% | $46B | $79B | 1.5x | 7.1x | ||
| $69 | +3% | $44B | $53B | 2.9x | 9.9x | ||
| $5 | -3% | $43B | $53B | 3.5x | 13.7x | ||
| $17 | -27% | $33B | $41B | 2.7x | 11.7x | ||
| $75 | +1% | $31B | $31B | 1.3x | 7.4x | ||
| $75 | +24% | $27B | $33B | 2.2x | 14.8x | ||
| $527 | +33% | $23B | $25B | 2.0x | 13.3x | ||
| $95 | -4% | $23B | $24B | 3.9x | 17.0x | ||
| $88 | -39% | $19B | $16B | 1.4x | 8.3x | ||
 | $27 | -11% | $18B | $21B | 1.4x | 7.6x | ||
 | $38 | -1% | $17B | $17B | 1.5x | 10.2x | ||
 | $8 | -4% | $14B | $12B | 2.0x | 14.3x | ||
| $72 | -12% | $14B | $16B | 3.9x | 12.3x | ||
| $11 | -18% | $11B | $12B | 7.0x | 34.0x | ||
 | $20 | +6% | $11B | $12B | 1.9x | 9.4x | ||
| $8 | +4% | $10B | $10B | 7.0x | 40.4x | ||
| $6 | -29% | $10B | $8B | 1.3x | 7.8x | ||
 | $270 | +424% | $10B | $10B | 8.2x | 31.7x | ||
| $6 | -- | $10B | $10B | 10.7x | 54.9x | ||
| $22 | -17% | $9B | $10B | 6.2x | 25.3x | ||
| $21 | +39% | $8B | $9B | 1.5x | 12.9x | ||
| $4 | -15% | $8B | $8B | 5.4x | 28.6x | ||
 | $16 | +46% | $6B | $10B | 2.0x | 11.3x | ||
| $20 | -28% | $6B | $5B | 8.4x | 26.8x | ||
| $79 | +6% | $5B | $5B | 1.7x | 11.8x | ||
| $17 | -10% | $5B | $4B | 1.3x | 8.3x | ||
| $53 | -8% | $4B | $5B | 1.6x | 6.9x | ||
| $25 | -20% | $4B | $4B | 9.8x | 28.6x | ||
 | $0 | +11% | $4B | $4B | 2.0x | 12.7x | ||
| $4 | +33% | $4B | $4B | 1.2x | 6.7x | ||
| $66 | +6% | $4B | $5B | 2.8x | 14.0x | ||
| $4 | -65% | $4B | $3B | 3.0x | 7.5x | ||
| $9 | -36% | $3B | $3B | 1.8x | 9.9x | ||
| $15 | +1% | $3B | $3B | 1.6x | 9.3x | ||
| $104 | -33% | $3B | $3B | 6.9x | 26.1x | ||
| $95 | -13% | $3B | $3B | 2.0x | 10.1x | ||
| $10 | -8% | $3B | $2B | 0.8x | 6.5x | ||
 | $2 | -- | $3B | $4B | 0.8x | 6.5x | ||
 | $18 | +4% | $3B | $2B | 1.2x | 8.2x | ||
| $67 | +2% | $3B | $3B | 1.0x | 5.4x | ||
| $57 | -30% | $3B | $4B | 3.4x | 10.2x | ||
| $81 | -7% | $3B | $3B | 7.7x | 27.1x | ||
| $156 | -26% | $3B | $2B | 0.4x | 6.4x | ||
 | $4 | -- | $3B | $2B | — | — | ||
| $6 | -29% | $2B | $2B | 1.7x | 10.5x | ||
| $1 | +21% | $2B | $2B | 5.5x | 15.6x | ||
| $28 | -24% | $2B | $2B | 2.2x | 10.0x | ||
| $5 | -10% | $2B | $2B | 2.2x | 18.4x | ||
| $0 | -23% | $2B | $2B | — | — | ||
 | $4 | +37% | $2B | $3B | 0.8x | 5.5x | ||
| $5 | -10% | $2B | $2B | 3.0x | 13.8x | ||
| $2 | -55% | $2B | $5B | 0.9x | 5.6x | ||
| $4 | -34% | $2B | $2B | 4.5x | 17.0x | ||
| $32 | +31% | $2B | $2B | 2.3x | 11.7x | ||
| $4 | +38% | $2B | $2B | 1.7x | 12.9x | ||
| $4 | -1% | $2B | $2B | — | — | ||
| $6 | +16% | $2B | $2B | 2.8x | 13.7x | ||
| $11 | -56% | $2B | $5B | 1.1x | 6.8x | ||
| $134 | +16% | $2B | $2B | 1.2x | 10.1x | ||
| $17 | +18% | $1B | $480M | — | — | ||
| $2 | +54% | $1B | $1B | 3.3x | 14.9x | ||
 | $14 | -8% | $1B | $1B | 1.2x | 7.9x | ||
| $55 | +8% | $1B | $2B | 1.0x | 7.8x | ||
| $4 | +37% | $1B | $1B | 4.5x | 48.7x | ||
 | $18 | +16% | $1B | $1B | 1.6x | 10.8x | ||
| $22 | -27% | $1B | $2B | 1.1x | 8.6x | ||
| $25 | +6% | $1B | $1B | 2.1x | 10.7x | ||
| $7 | +32% | $993M | $1B | 1.6x | 6.8x | ||
 | $1 | +12% | $910M | $788M | 1.7x | 7.4x | ||
| $53 | -4% | $873M | $842M | 5.8x | 18.4x | ||
| $2 | +154% | $827M | $881M | 0.8x | 7.2x | ||
| $14 | -77% | $810M | $1B | 1.3x | 7.5x | ||
 | $19 | +93% | $695M | $931M | 1.1x | 5.7x | ||
 | $493 | -3% | $694M | $744M | — | — | ||
 | $13 | -14% | $693M | $666M | — | — | ||
| $0 | -9% | $639M | $424M | — | — | ||
| $57 | +96% | $610M | $671M | 1.5x | 9.1x | ||
| $1 | +6% | $463M | $594M | 0.8x | 6.4x | ||
| $4 | -- | $449M | $544M | 2.8x | 11.1x | ||
| $17 | -39% | $389M | $1B | 0.7x | 7.0x | ||
| $8 | +19% | $369M | $436M | 0.3x | — | ||
 | -- | -- | $352M | $386M | 1.1x | 5.9x | ||
| $3 | -37% | $340M | $265M | 0.7x | 12.2x | ||
| $4 | -62% | $282M | $383M | 1.3x | (21.5x) | ||
| $2 | +81% | $280M | $312M | — | — | ||
 | $3 | -59% | $273M | $907M | 0.4x | 4.3x | ||
| $3 | -43% | $233M | $224M | 1.5x | 7.2x | ||
| $4 | -24% | $213M | $126M | 0.7x | 4.3x | ||
| $1 | +46% | $207M | $239M | 0.6x | 7.5x | ||
| $4 | -48% | $185M | $155M | 0.8x | 10.5x | ||
| $5 | +0% | $177M | $252M | — | — |
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.